– Professor Alastair Compston from the University of Cambridge, principal investigator of the MS research
Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
A drug which is said to "reboot" the immune system has been shown to be an effective treatment for multiple sclerosis (MS), a study has found.